Wang et al. evaluated a cohort of 107 NPM1-mut AMLs characterized for the mutational profile by NGS and treated with risk-adapted therapy; the patients were subdivided into three groups: patients without MDS-related gene mutations (group A), patients with concurrent FLT3-ITD mutations (group B), and patients with MDS-related mutations (group C) [80]. This evidence concerns the gene FLT3 and myelodysplastic syndrome.